Loading...
•
Dec 31, 2021
Heron Therapeutics Q4 2021 Earnings Report
Heron Therapeutics reported financial results for Q4 2021 and highlighted recent corporate updates.
Key Takeaways
Heron Therapeutics reported net product sales of $20.7 million for the three months ended December 31, 2021. The company's net loss for the same period was $54.6 million, or $0.54 per share.
ZYNRELEF has received 260 formulary approvals since initial launch in July 2021, with over a 90% hospital approval rate and over 60% of approvals have been for unrestricted usage.
Over 300 unique accounts purchased ZYNRELEF with 70% of those accounts reordering the product.
FDA approval received in December 2021 for a significant indication expansion of ZYNRELEF, now covering approximately 7 million procedures annually.
CMS has issued a specific C-code in November 2021 for ZYNRELEF to support separate reimbursement for Medicare patients in the ASC setting of care.
Heron Therapeutics
Heron Therapeutics
Heron Therapeutics Revenue by Segment
Revenue by Segment
CINVANTI Revenue
CapyFin.comSUSTOL Revenue
CapyFin.comZYNRELEF Revenue
CapyFin.com Forward Guidance
Heron currently expects the first quarter of 2022 net product sales for the oncology care franchise in the range of $20 million to $22 million. The Company is not providing full-year 2022 financial guidance at this time due to the uncertainty around the COVID-19 pandemic and its impact on patient care.
Revenue & Expenses
Visualization of income flow from segment revenue to net income